Clinical Trials on Sinonasal Malignancies in China

Total 185 results

Eye & ENT Hospital of Fudan University
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Recruiting

Single Arm Study of Induction Chemoradiotherapy Combined With Surgery in the Treatment of Locally Advanced SNMM (SNMM)

Mucosal Melanoma | Sinonasal Melanoma

China
Xiao Chen

Recruiting

Role of FAPI PET/MR Combined With Gadoxetate Disodium in Assessing Hepatic Malignancies

Hepatic Malignancies

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Study Evaluating the Safety, Tolerability, and Initial Efficacy of IBI110 in Subjects With Advanced Malignant Tumors

Advanced Malignancies

China
Innovent Biologics (Suzhou) Co. Ltd.

Withdrawn

IBI397 or Combination Therapies in Patients With Advanced Malignancies

Advanced Malignancies

China
Southwest Hospital, China

Unknown

A Clinical Research of CD33-Targeted CAR-T in Myeloid Malignancies

Myeloid Malignancies

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

Study of IBI323 in Patients With Advanced Malignancies

Advanced Malignancies

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Safety and Efficacy of IBI322 in Chinese Subjects With Advanced Malignant Tumors

Advanced Malignancies

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Phase 1 Study Evaluating the Safety, Tolerability, and Initial Efficacy of IBI188 in Advanced Malignancies

Advanced Malignancies

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of TQB3455 Tablets in Subjects With Advanced Malignancies

Advanced Malignancies

China
Han weidong

Unknown

Anti-PD-1 Antibody Alone or in Combination With Decitabine/Chemotherapy in Relapsed or Refractory Malignancies

Malignancies Multiple

China
Shanghai Jiao Tong University School of Medicine

Completed

Fludarabine/Busulfan and Cyclophosphamide Conditioning for Adult Lymphoid Malignancies

Lymphoid Malignancies

China
Shandong TheraWisdom Biopharma Co., Ltd.

Recruiting

Safety, Tolerability, PK, PD, Immunogenicity and Efficacy of TWP-102 in Patients With Advanced Malignancies.

Advanced Malignancies

China
Zhujiang Hospital
Guangzhou BR

Completed

AssesSment of Early-deteCtion basEd oN liquiD Biopsy in Hepatobiliary Cancer Malignancies (ASCEND-Hep)

Hepatobiliary Malignancies

China
Zhe Jiang Hisun Bioray Bio-pharmaceu tical Co.Ltd

Not yet recruiting

A Phase I Study of BRY812 for Injection Alone in Subjects With Advanced Malignancies

Advanced Malignancies

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Study of SHR-A1811 in Subjects With Gynaecologic Oncology

Gynaecological Malignancies

China
Sichuan University

Recruiting

Fractionated Busulfan Conditioning Regimen for Allo-HSCT in Non-remission Myeloid Malignancies

Myeloid Malignancies

China
Zhe Jiang Hisun Bioray Bio-pharmaceu tical Co.Ltd

Not yet recruiting

Phase I Clinical Study of BR105 Injection (BR105-I)

Advanced Malignancies

China
Beijing Mabworks Biotech Co., Ltd.

Recruiting

A Clinical Study of MIL93 in Solid Tumors.

Advanced Malignancies

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study of SHR-1501 in Patients With Advanced Tumors

Advanced Malignancies

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-T-cell Immunoreceptor With Ig and ITIM Domains (TIGIT) Monoclonal Antibody Injection (IBI939) in Subjects With Advanced Malignant Tumors

Advanced Malignancies

China
Southwest Hospital, China

Unknown

A Clinical Research of LeY-Targeted CAR-T in Myeloid Malignancies

Myeloid Malignancies

China
Shanghai Tongji Hospital, Tongji University School...

Recruiting

Anti-CD19-CAR-T Cells in Relapsed/Refractory B-cell Tumor Patients.

B Cell Malignancies

China
AstraZeneca

Completed

10mg ZD4054 (Zibotentan) PK Study in Male, Elderly Chinese Patients With Advanced Solid Malignancies

Advanced Solid Malignancies

China
TransThera Sciences (Nanjing), Inc.

Recruiting

A Phase 1 Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies

B-Cell Malignancies

China
Shenzhen Geno-Immune Medical Institute

Recruiting

CD19/22 Bi-specific CAR-T Cell Therapy

B Cell Malignancies

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Phase I Study of HRS2300 or Combined With SHR-1316 or SHR-1701 or Trametinib or Almonertinib in Patients With Advanced Malignancies

Advanced Malignancies

China
Shanghai Escugen Biotechnology Co., Ltd

Recruiting

A Phase 1 Study of ESG206 in Adult Subjects With B-cell Lymphoid Malignancies

B-cell Lymphoid Malignancies

China
Shenzhen Geno-Immune Medical Institute

Recruiting

CD19/79b Bi-specific CAR-T Cell Therapy

B Cell Malignancies

China
Shenzhen Geno-Immune Medical Institute

Recruiting

CD19/70 Bi-specific CAR-T Cell Therapy

B Cell Malignancies

China
Sinocelltech Ltd.

Recruiting

A Clinical Study of SCTC21C in Participants With CD38+ Hematologic Malignancies

Relapsed or Refractory Hematologic Malignancies

China
AstraZeneca

Completed

A Study to Determine the Pharmacokinetics of Cediranib in Chinese Patients With Advanced Solid Malignancies

Advanced Solid Malignancies

China
BioRay Pharmaceutical Co., Ltd.

Not yet recruiting

A Phase I Study of BR115 for Injection Alone in Subjects With Advanced Solid Malignancies

Advanced Solid Malignancies

China
First Affiliated Hospital of Fujian Medical University

Recruiting

A Study of Adebrelimab in Combination With Apatinib Gemcitabine and Cisplatin in Biliary Tract Malignancies

Biliary Tract Malignancies

China
Institute of Hematology & Blood Diseases Hospital
Juventas Cell Therapy Ltd.

Available

A Clinical Study of CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies

Relapsed and Refractory Hematological Malignancies

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Study of TQB3473 Tablets in Subjects With Relapsed or Refractory Hematological Malignancies

Relapsed/Refractory Hematological Malignancies

China
Shanghai Hengrui Pharmaceutical Co., Ltd.

Recruiting

A Phase 1 Study of SHR-A2102 in Subjects With Advanced Solid Tumors.

Advanced Or Metastatic Solid Tumor Malignancies

China
He Huang
Yake Biotechnology Ltd.

Recruiting

A Study of CD20/CD22 Targeted CAR T-cell Therapy for Relapsed or Refractory Lymphoid Malignancies

Relapsed and Refractory | Lymphoid Hematological Malignancies

China
Shandong University
Juventas Cell Therapy Ltd.

Unknown

A Clinical Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Injection (CNCT19) in the Treatment of Cluster of Differentiation 19 (CD19) Positive Relapsed or Refractory B Cell Malignancies

Relapsed or Refractory Hematological Malignancies

China
Affiliated Hospital to Academy of Military Medical...
Beijing JD Biotech Co. LTD.

Recruiting

CAR-NK Targeted CD19 for r/r B-cell Malignancies

Adult Relapsed/Refractory B-cell Hematologic Malignancies

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Peking University People's Hospital; The First Affiliated Hospital of Zhengzhou... and other collaborators

Recruiting

PA3-17 Injection Treatment of Adult Patients With CD7-positive Relapsed/Refractory Lymphoid Hematologic Malignancies

CD7-positive Relapsed/Refractory Lymphoid Hematologic Malignancies

China
Minghui Pharmaceutical (Shanghai) LTD

Recruiting

This is a Phase 1 Study of MH048 in Patients With Selected Relapsed/Refractory B-cell Malignancies

Relapsed/Refractory B-cell Malignancies

China
Sunshine Lake Pharma Co., Ltd.

Active, not recruiting

A Study to Evaluate the Tolerability, Safety, Pharmacokinetics of HEC89736 in Patients With Relapsed or Refractory B-cell Hematologic Malignancies

Relapsed or Refractory B-cell Hematologic Malignancies

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Anhui Provincial Hospital

Not yet recruiting

UTAA09 Injection in the Treatment of Relapsed/Refractory Hematolymphatic Malignancies.

CD19-positive Relapsed or Refractory B-cell Malignancies

China
Ningbo Cancer Hospital

Unknown

PD-1 Antibody Expressing CAR-T Cells for EGFR Family Member Positive Advanced Solid Tumor

Advanced Malignancies | PD-1 Antibody | CAR-T Cells

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study of SHR-1501 Combined With SHR-1316 in Patients With Advanced Tumors

Advanced Malignancies

Australia, China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

Safety, Tolerability, Pharmacokinetic Characteristics, and Efficacy of CM369 in Advanced Solid Tumors & Hematologic Malignancies

Advanced Solid Tumors and Hematologic Malignancies

China
Anhui Provincial Hospital

Recruiting

An Observational Study of Menopausal Symptom in Patients With Gynecological Malignancy After Oophorectomy

Bone Loss | Menopausal Symptoms | Gynecological Malignancies

China
Shenzhen Geno-Immune Medical Institute
The Second Affiliated Hospital of Hainan Medical University; Beijing Jingdu...

Recruiting

4SCAR19U T Cells Targeting B Cell Malignancies

B Cell Malignancies

China
Zai Lab (Shanghai) Co., Ltd.

Completed

To Evaluate Pharmacokinetics of Tisotumab Vedotin in Chinese Subjects With Metastatic or Recurrent Solid Malignancies

Solid Malignancies

China
Novartis Pharmaceuticals

Completed

Phase I Study of PDR001 in Patients With Advanced Malignancies.

Advanced Malignancies

Japan

Clinical Trials on Sinonasal Malignancies in China

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Spain

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations